timothy sykes logo

Stock News

MNKD Shares Plunge: Should Investors Worry?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 9/2/2025, 9:19 am ET 9/2/2025, 9:19 am ET | 5 min 5 min read
MNKD Shares Plunge: Should Investors Worry? Thumbnail

MannKind Corporation’s stocks have been trading up by 40.31 percent following promising clinical trial advancements in diabetes treatment.

  • MannKind unveiled a significant financing deal with Blackstone valued at up to $500M. This arrangement provides essential funds for advancing its growth goals without impacting existing shareholders.

  • The second quarter earnings report for MannKind revealed a shortfall in expected non-GAAP EPS at $0.05 compared to a projection of $0.08. However, noteworthy progress in its development pipeline offers optimism for its future prospects.

  • RBC has reduced its price target for MannKind, bringing it down from $8 to $7, yet it maintains an ‘Outperform’ rating, signalling belief in the company’s potential despite current challenges.

Candlestick Chart

Live Update At 09:18:51 EST: On Tuesday, September 02, 2025 MannKind Corporation stock [NASDAQ: MNKD] is trending up by 40.31%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

MannKind’s Financial Insights

When engaging in trading activities, it’s crucial to maintain a disciplined approach. The emotional rollercoaster that often accompanies market fluctuations can lead to impulsive decisions that are rarely beneficial. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” By adhering to a consistent strategy, traders can better manage risks and enhance the potential for success. This means setting clear objectives and sticking to them, regardless of temporary market shifts that might trigger emotional responses.

MannKind’s Q2 results were a mixed bag. The company’s revenue touched $76.5M, which was short of analysts’ expectations of $78.78M. This shortfall, coupled with adjusted EPS landing at $0.05 rather than the anticipated $0.08, stirred apprehensions in the market.

The intrigue doesn’t end there. Across the revenue channels, there is a noticeable uptick, and simultaneously, impressive momentum in R&D became apparent. Their Afrezza biologics license aimed at pediatric uses is noteworthy. This push is akin to explorers braving uncharted waters in hopes of gold at the end.

On the investor front, MannKind’s PE ratio of 45.9 indicates a jittery yet hopeful market, expecting potential growth. With their focus on innovative approaches to disease treatment and smart financial maneuvering, such as the Blackstone deal, they are gearing up for a promising future.

Observations from their statement showed a stable current ratio of 2.4, hinting at financial solidity. Amid all this, their long-term risk management and short-term liquidity strategies give the company a stable footing.

Deconstructing Recent Moves

Amidst the whirlwind of numbers, one can’t overlook the unique strategic shifts. The new Blackstone deal is big news. Imagine a knight being handed a new sword; that’s what $500M in non-dilutive funding signifies for MannKind. This included an upfront $75M and optionality of additional loans, introducing robust cash flow which facilitates further far-reaching projects.

Moreover, their venture into new territories through trial performances is akin to expanding horizons and setting sails for new adventures. From charting courses in lung disease treatments to advancing pediatric Afrezza applications, these strides may well write MannKind’s success stories in the annals of biotech.

Nevertheless, not all is rosy. Analysts bringing down price targets have cast shadows. Still, RBC’s faith in MannKind, with an ‘Outperform’ status, suggests the market sees potential blooms amidst existing thorns.

More Breaking News

Conclusion

With recent price fluctuations and subsequent challenges, MannKind finds itself at a critical crossroads. It’s a tale as old as time: new ventures versus market apprehensions. Their innovative strides and funding infusions resemble a young sapling eager to grow amid towering forest giants.

Though current numbers suggest a bumpy ride, MannKind’s strategic partnerships promise resilience and growth, paving the path for an interesting future. Traders must weigh this complex narrative with deft scrutiny. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Are they poised for a rebound? Only time will tell in this captivating saga.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”